# Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

Study · id `cardio:ct-nct04168203` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04168203](<https://clinicaltrials.gov/study/NCT04168203>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04168203

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 600 participants.

## Technical summary

Registry record NCT04168203. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-01 (actual); primary completion 2023-11-30 (actual). Results posted on 2025-09-30.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 600 participants (enrolled count; ClinicalTrials.gov record NCT04168203, source copy `cardio:ctgov-nct04168203-2025-11-14`, retrieved 2026-10-31)
- Started: 2021-03-01 (actual) (ClinicalTrials.gov record NCT04168203, source copy `cardio:ctgov-nct04168203-2025-11-14`, retrieved 2026-10-31)
- Primary completion: 2023-11-30 (actual) (ClinicalTrials.gov record NCT04168203, source copy `cardio:ctgov-nct04168203-2025-11-14`, retrieved 2026-10-31)
- Completion: 2025-04-08 (actual) (ClinicalTrials.gov record NCT04168203, source copy `cardio:ctgov-nct04168203-2025-11-14`, retrieved 2026-10-31)
- Results first posted: 2025-09-30 (ClinicalTrials.gov record NCT04168203, source copy `cardio:ctgov-nct04168203-2025-11-14`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT04168203, source copy `cardio:ctgov-nct04168203-2025-11-14`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04168203-2025-11-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
- Acronym: HI-PRO
- Condition: Deep Vein Thrombosis
- Condition: Pulmonary Embolism
- Condition: Venous Thromboembolism
- Intervention (Drug): Apixaban 2.5 MG
- Intervention (Drug): Placebo oral tablet
- Lead sponsor: Brigham and Women's Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (`cardio:pubmed-40888734`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c64f454cf97c9f6c7b967b249cfe7c47f44cbc20a0776b27bf639719d904496a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
